|
1
|
Inda-Webb ME, Jimenez M, Liu Q, Phan NV, Ahn J, Steiger C, Wentworth A, Riaz A, Zirtiloglu T, Wong K, Ishida K, Fabian N, Jenkins J, Kuosmanen J, Madani W, McNally R, Lai Y, Hayward A, Mimee M, Nadeau P, Chandrakasan AP, Traverso G, Yazicigil RT, Lu TK. Sub-1.4 cm 3 capsule for detecting labile inflammatory biomarkers in situ. Nature 2023; 620:386-392. [PMID: 37495692 DOI: 10.1038/s41586-023-06369-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 06/26/2023] [Indexed: 07/28/2023]
Abstract
Transient molecules in the gastrointestinal tract such as nitric oxide and hydrogen sulfide are key signals and mediators of inflammation. Owing to their highly reactive nature and extremely short lifetime in the body, these molecules are difficult to detect. Here we develop a miniaturized device that integrates genetically engineered probiotic biosensors with a custom-designed photodetector and readout chip to track these molecules in the gastrointestinal tract. Leveraging the molecular specificity of living sensors1, we genetically encoded bacteria to respond to inflammation-associated molecules by producing luminescence. Low-power electronic readout circuits2 integrated into the device convert the light emitted by the encapsulated bacteria to a wireless signal. We demonstrate in vivo biosensor monitoring in the gastrointestinal tract of small and large animal models and the integration of all components into a sub-1.4 cm3 form factor that is compatible with ingestion and capable of supporting wireless communication. With this device, diseases such as inflammatory bowel disease could be diagnosed earlier than is currently possible, and disease progression could be more accurately tracked. The wireless detection of short-lived, disease-associated molecules with our device could also support timely communication between patients and caregivers, as well as remote personalized care.
Collapse
Affiliation(s)
- M E Inda-Webb
- Synthetic Biology Group, MIT Synthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- Research Laboratory of Electronics, Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - M Jimenez
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Q Liu
- Electrical and Computer Engineering Department, Boston University, Boston, MA, USA
| | - N V Phan
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - J Ahn
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - C Steiger
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - A Wentworth
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - A Riaz
- Electrical and Computer Engineering Department, Boston University, Boston, MA, USA
| | - T Zirtiloglu
- Electrical and Computer Engineering Department, Boston University, Boston, MA, USA
| | - K Wong
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - K Ishida
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - N Fabian
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Comparative Medicine, MIT, Cambridge, MA, USA
| | - J Jenkins
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - J Kuosmanen
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - W Madani
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - R McNally
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Y Lai
- Synthetic Biology Group, MIT Synthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- Research Laboratory of Electronics, Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - A Hayward
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Division of Comparative Medicine, MIT, Cambridge, MA, USA
| | - M Mimee
- Department of Microbiology, Biological Sciences Division and Pritzker School of Molecular Engineering, The University of Chicago, Chicago, IL, USA
| | | | - A P Chandrakasan
- Department of Electrical Engineering and Computer Science, MIT, Cambridge, MA, USA
| | - G Traverso
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
- The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
- Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
| | - R T Yazicigil
- Electrical and Computer Engineering Department, Boston University, Boston, MA, USA.
| | - T K Lu
- Synthetic Biology Group, MIT Synthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
- Research Laboratory of Electronics, Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
- Senti Biosciences, South San Francisco, CA, USA.
| |
Collapse
|
|
2
|
Vahl JM, Wigand MC, Denkinger M, Dallmeier D, Steiger C, Welke C, Kuhn P, Idel C, Doescher J, von Witzleben A, Brand M, Marienfeld R, Möller P, Theodoraki MN, Greve J, Schuler PJ, Brunner C, Hoffmann TK, Laban S. Increasing Mean Age of Head and Neck Cancer Patients at a German Tertiary Referral Center. Cancers (Basel) 2021; 13:cancers13040832. [PMID: 33671152 PMCID: PMC7922863 DOI: 10.3390/cancers13040832] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 02/03/2021] [Accepted: 02/08/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND The impact of demographic change on the age at diagnosis in German head and neck cancer (HNC) patients is unclear. Here we present an evaluation of aging trends in HNC at a tertiary referral center. METHODS Retrospective cohort study on aging trends at the initial diagnosis of newly diagnosed patients with HNC between 2004 and 2018 at the head and neck cancer center Ulm in relation to demographic data of the catchment area. RESULTS The study population consisted of 2450 individuals diagnosed with HNC with a mean age of 62.84 (±11.67) years. We observed a significant increase in annual incidence rates and mean age over time. Mean age among HNC patients increased significantly more than among the population in the catchment area. Whereas the incidence rate of patients <50 years did not change, the incidence of HNC patients aged ≥70 years increased the most. The mean patient age in the main tumor sites increased significantly. Surprisingly, HPV-positive patients were not younger than HPV-negative patients, but showed a non-significant trend towards a higher mean age (63.0 vs. 60.7 years). CONCLUSIONS Increasing incidence rates in older patients pose a challenge for health care systems. A nationwide study is needed to assess the dynamics and impact of aging on the incidence of HNC.
Collapse
Affiliation(s)
- Julius M. Vahl
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Marlene C. Wigand
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Michael Denkinger
- Agaplesion Bethesda Ulm, Geriatric Research Ulm University and Geriatric Center, 89073 Ulm, Germany; (M.D.); (D.D.)
| | - Dhayana Dallmeier
- Agaplesion Bethesda Ulm, Geriatric Research Ulm University and Geriatric Center, 89073 Ulm, Germany; (M.D.); (D.D.)
| | - Chiara Steiger
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Claudia Welke
- Clinical Cancer Registry, Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89081 Ulm, Germany; (C.W.); (P.K.)
| | - Peter Kuhn
- Clinical Cancer Registry, Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89081 Ulm, Germany; (C.W.); (P.K.)
| | - Christian Idel
- Department of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, Germany;
| | - Johannes Doescher
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Adrian von Witzleben
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
- Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK
| | - Matthias Brand
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Ralf Marienfeld
- Institute of Pathology, University Medical Center Ulm, 89081 Ulm, Germany; (R.M.); (P.M.)
| | - Peter Möller
- Institute of Pathology, University Medical Center Ulm, 89081 Ulm, Germany; (R.M.); (P.M.)
| | - Marie-Nicole Theodoraki
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Jens Greve
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Patrick J. Schuler
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Cornelia Brunner
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Thomas K. Hoffmann
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
| | - Simon Laban
- Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, 89075 Ulm, Germany; (J.M.V.); (M.C.W.); (C.S.); (J.D.); (A.v.W.); (M.B.); (M.-N.T.); (J.G.); (P.J.S.); (C.B.); (T.K.H.)
- Correspondence: ; Tel.: +49-731-5005-9501
| |
Collapse
|
|
4
|
Maggio ABR, Martin X, Steiger C, Tabard-Fougère A, Dayer R, Delhumeau C, Ceroni D. Do teenagers return to normal physical activity levels after limb fractures? A longitudinal, accelerometry-based, activity monitoring study. J Child Orthop 2019; 13:575-581. [PMID: 31908674 PMCID: PMC6924123 DOI: 10.1302/1863-2548.13.190082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE This study aimed to elucidate whether levels of physical activity (PA) return to normal after bone healing or whether long-term behavioural changes in PA are to be expected in children and teenagers who have sustained limb fractures. METHODS In all, 100 children and teenagers with a first episode of limb fracture and 100 sex- and age-matched healthy controls (CTRL) were recruited for a prospective study. PA in limb fracture patients was assessed at 18-month follow-up using accelerometer measurements, and values were compared with those of CTRL. Time spent in PA at different levels of intensity was determined for each participant and expressed in minutes and as a percentage of total validly measured time. RESULTS Mean levels of PA at different levels of intensity by previously injured children and teenagers were similar than CTRL (42 sets of paired data). However, time spent in moderate-to-vigorous PA (MVPA) was lower than 60 minutes among limb-fracture patients at 18-month follow-up. CONCLUSION The amount of skeletal loading in children and teenagers returns to normal values by 18 months after limb fracture. Even if time spent in MVPA is not significantly lower in children and teenagers with limb fractures, it no longer reached the international recommendations for school-aged children (MVPA > 60 minutes), which may be interpreted as a lifestyle modification or a behavioural change to avoid new trauma. LEVEL OF EVIDENCE II.
Collapse
Affiliation(s)
- A. B. R. Maggio
- Health and movement consultation, Pediatric Cardiology Unit, Department of Child and Adolescent, University of Geneva Hospitals and University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - X. Martin
- Pediatric Orthopedic Unit, Department of Child and Adolescent, University of Geneva Hospitals and University of Geneva Faculty of Medicine, Geneva, Switzerland,Clinical Epidemiology Service, Department of Child and Adolescent, University of Geneva Hospitals and University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - C. Steiger
- Pediatric Orthopedic Unit, Department of Child and Adolescent, University of Geneva Hospitals and University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - A. Tabard-Fougère
- Pediatric Orthopedic Unit, Department of Child and Adolescent, University of Geneva Hospitals and University of Geneva Faculty of Medicine, Geneva, Switzerland,Correspondence should be sent to A. Tabard-Fougère, Pediatric Orthopedic Unit, Department of Child and Adolescent, Children’s Hospital, 6 Rue Willy Donzé, 1211 Geneva 14 / Switzerland. E-mail:
| | - R. Dayer
- Pediatric Orthopedic Unit, Department of Child and Adolescent, University of Geneva Hospitals and University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - C. Delhumeau
- Clinical Epidemiology Service, Department of Child and Adolescent, University of Geneva Hospitals and University of Geneva Faculty of Medicine, Geneva, Switzerland
| | - D. Ceroni
- Pediatric Orthopedic Unit, Department of Child and Adolescent, University of Geneva Hospitals and University of Geneva Faculty of Medicine, Geneva, Switzerland
| |
Collapse
|
|
7
|
Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 2005; 92:342-9. [PMID: 15655555 PMCID: PMC2361858 DOI: 10.1038/sj.bjc.6602310] [Citation(s) in RCA: 109] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
MT201 is a fully human monoclonal IgG1 antibody with moderate affinity for epithelial cell adhesion molecule (Ep-CAM) being clinically developed for the treatment of carcinomas. Like many other clinically validated IgG1 monoclonal antibodies, MT201 primarily acts by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Here, we analysed ADCC and CDC induced by MT201 and, as reference, trastuzumab against a panel of nine human breast cancer cell lines expressing distinct surface levels of Ep-CAM and human epithelial growth factor receptor type 2 antigen. Maximal cell lysis by ADCC by MT201 and trastuzumab in the presence of peripheral mononuclear cells did not significantly differ when averaged over the nine cell lines, but showed marked differences with respect to individual cell lines. The extent of cell lysis at intermediate surface target density was highly variable, suggesting a dominant influence of other susceptibility factors. Only one breast cancer cell line was eliminated via CDC, but only by MT201. Resistance to CDC appeared to correlate with high expression levels of complement resistance factors. Our present data as well as recent data on the prevalence and prognostic relevance of Ep-CAM expression in metastatic breast cancer suggest that Ep-CAM-specific monoclonal IgG1 antibodies may have a significant therapeutic potential in the treatment of breast cancer.
Collapse
Affiliation(s)
- N Prang
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - S Preithner
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - K Brischwein
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - P Göster
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - A Wöppel
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - J Müller
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - C Steiger
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - M Peters
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - P A Baeuerle
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
| | - A J da Silva
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany
- Micromet AG, Staffelseestrasse 2, Munich 81477, Germany. E-mail:
| |
Collapse
|